A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005668|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : August 27, 2010
To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma.
Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus. The infection can spread from the lungs through the blood to other organs. Aspergilloma can be life-threatening; therefore, an effective treatment is needed.
|Condition or disease||Intervention/treatment||Phase|
|Aspergillosis Lung Diseases, Fungal||Drug: Itraconazole oral solution||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||96 participants|
|Official Title:||A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma|
|Study Completion Date :||November 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005668
|United States, Alabama|
|Mary Ellen Bradley|
|Birmingham, Alabama, United States, 35294|